Grifols (GIFLF) Retained Earnings (2009 - 2025)
Grifols' (GIFLF) quarterly Retained Earnings came in at $4.9 billion in Q4 2025, up 12.45% on a YoY basis from $4.3 billion in Q4 2024, and up 12.45% quarter-over-quarter from $4.3 billion in Q4 2024.
Analysis
Grifols (GIFLF) Retained Earnings (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Retained Earnings for 17 consecutive years, with $4.9 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 12.45% year-over-year to $4.9 billion; the trailing twelve-month figure through Dec 2025 stood at $4.9 billion (up 12.45% YoY), and the FY2025 full-year result was $4.7 billion, up 9.15% from the prior year.
- Retained Earnings grew to $4.9 billion in Q4 2025 per GIFLF's latest filing, from $4.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $4.9 billion in Q4 2025 and bottomed at $4.1 billion in Q4 2022.
- Historically, Retained Earnings has averaged $4.5 billion across 5 years, with a median of $4.3 billion in 2023.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings decreased 12.55% in 2022, then increased 12.45% in 2025.
- Over 5 years, Retained Earnings stood at $4.7 billion in 2021, then slipped by 12.55% to $4.1 billion in 2022, then climbed by 5.14% to $4.3 billion in 2023, then dropped by 0.36% to $4.3 billion in 2024, then climbed by 12.45% to $4.9 billion in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $4.9 billion, $4.3 billion, and $4.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 4.87 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4.87 Bn |
| Dec 31, 2024 | 4.33 Bn |
| Dec 31, 2023 | 4.35 Bn |
| Dec 31, 2022 | 4.14 Bn |
| Dec 31, 2021 | 4.73 Bn |
| Dec 31, 2020 | 4.50 Bn |
| Sep 30, 2020 | 4.71 Bn |
| Mar 31, 2020 | 4.44 Bn |
| Dec 31, 2019 | 3.33 Bn |
| Sep 30, 2019 | 3.10 Bn |
| Dec 31, 2018 | 2.79 Bn |
| Sep 30, 2018 | 2.85 Bn |
| Jun 30, 2018 | 2.93 Bn |
| Mar 31, 2018 | 3.73 Bn |
| Dec 31, 2017 | 2.39 Bn |
| Jun 30, 2017 | 2.23 Bn |
| Dec 31, 2016 | 1.83 Bn |
| Sep 30, 2016 | 1.89 Bn |
| Jun 30, 2016 | 1.92 Bn |
| Dec 31, 2015 | 1.50 Bn |